key: cord-0789473-3ustfkf0 authors: Jain, Snigdha; Santhosh, Lekshmi title: On Treatments and Tests Deferred: Preparing for Collateral Damage from COVID-19 date: 2020-11-03 journal: Ann Am Thorac Soc DOI: 10.1513/annalsats.202004-387vp sha: c2e039eb9bcb8b3742e37338b43b6343f06e3076 doc_id: 789473 cord_uid: 3ustfkf0 nan On a new-normal afternoon of calling patients virtually for follow-up visits, I was jolted by a conversation that typically would have ended with a seamlessly executed plan. I called Ms. M, my 67-year old patient with interstitial lung disease. She promptly answered the phone, having been recently reminded of her virtual appointment by our clinic coordinator. She explained that she was still coughing, and that perhaps her dyspnea had worsened, though it was hard to tell as she was sheltering in place. As our conversation went on, I was slowly becoming aware that the challenges of this visit were going to transcend beyond the initial stumble of how to check someone into the virtual waiting room. Exactly how far could she walk before having to stop because of dyspnea? Did her lungs sound different? Had her forced expiratory volume in 1 second declined? Was her fibrosis progressing? Was a computed tomography (CT) scan worth exposing her to the risk of coronavirus disease infection? Would I increase immunosuppression even if it was progressing? Each clinic visit now posed these new and unanticipated dilemmas. As we grapple with the COVID-19 pandemic, much attention has rightfully focused on overcrowded emergency rooms and intensive care units (ICUs). However, signs of subtler collateral damage for non-COVID conditions are starting to emerge across specialties (1) (2) (3) (4) . Telehealth visits have provided some degree of normalcy to our lives (5) by offering opportunities to communicate with patients, hear their concerns, allay anxiety, and discuss symptoms. Moreover, they allow patients and family members to avoid logistical barriers, such as parking and transportation; these benefits have led to dramatically increased rates of telehealth appointments (6) . However, as outpatient pulmonary medicine physicians, we wonder how to optimally address the diagnosis and treatment of our patients' lung diseases during this pandemic. In addition to the unease we feel from being unable to perform our physical exam maneuvers-our inability to clearly see clubbing across the computer screen or hear the high-pitched inspiratory squeaks-the tests that take the place of our eyes and ears are equally missing in these times. The unique risk of aerosol generation accompanying pulmonary function tests (PFTs) and bronchoscopies has caused most centers to limit their performance. CT, the next best diagnostic test in the absence of histopathology, also bears the risk of exposing the patient to the healthcare environment. Pulmonary rehabilitation, a successful therapeutic intervention, has been closed for the same reason. Deferring these diagnostic and treatment modalities may seem inconsequential in the short term, but with the uncertain trajectory of the pandemic, how long must patients wait for these "elective" procedures? And will their absence drive up exacerbations and admissions for chronic lung disease, as has been predicted for other conditions (7, 8) ? Beyond these challenges, patients are also avoiding accessing the healthcare system as a whole, as during the Ebola outbreak, leading to rise in mortality for other conditions (9) . As emergency non-COVID cases, such as heart attacks and strokes (10) (11) (12) and hospitalizations for chronic conditions, such as heart failure and cirrhosis, decline across hospitals (13, 14) , we are also seeing increased all-cause mortality, raising concerns for even more devastating consequences of the pandemic (11, 15, 16) . Each clinic visit leaves us haunted, imagining a patient with massive hemoptysis because of progression of undiagnosed lung cancer or one with worsening dyspnea due to uncontrolled inflammation in the absence of adequate immunosuppression. To prevent a postpandemic wave of deferred diagnoses and unchecked disease progression, we need to strategically plan and restructure care delivery for outpatient pulmonary medicine. We describe the following three major domains that deserve consideration: before the visit, during the visit, and after the visit. Explicitly discuss follow-up needs with the patient and reach a shared decision on the timeline and modality of follow-up visit (in-person vs. virtual). Drive-through options for laboratory testing and pharmacy pick-up or delivery should be prioritized when available. We also suggest exploring opportunities for home-based monitoring and therapy wherever possible. For patients in whom frequent spirometric assessments are believed to be necessary and useful in guiding treatment, home-based spirometry should be considered to minimize exposure risk (18, 19) . Opportunities for virtual pulmonary rehabilitation should be explored (20) , and grounds gained on enhanced telehealth reimbursement practices should be retained beyond the acute phase of the pandemic. In this section, we focus on areas of uncertainty, or the "known unknowns," in which the pulmonary community will need to work together and in collaboration with other disciplines to tackle the unique challenges in delivering care in the postacute phase of the pandemic. Although consensus disease-specific recommendations from experts would help guide clinicians in certain areas, many questions demand the generation of new evidence to enable effective disease management in the context of altered, and often reduced, monitoring. A few examples are as follows: 1) Can PFTs and radiologic monitoring be spaced out without compromising the management of specific interstitial lung diseases? 2) Should laboratory-based biomarkers be investigated in comparison with current disease monitoring approaches such as PFTs and CT scans? 3) Are certain immunosuppressive agents safer than others with regard to the risk of acquiring coronavirus-related illness? 4) Could a tiered approach be developed to inform decisions about immunosuppression by integrating severity of illness, risk of infection, and anticipated outcome from the drug, as has been attempted in oncology (21)? 5) Should step-down of controller medications be avoided during this time to minimize the risk of exacerbations? In addition, there is a need for studying the validity, feasibility, and efficacy of homebased monitoring and treatment tools, such as spirometry, accelerometers, and virtual pulmonary rehabilitation, to allow a realistic consideration of their deployment and use in the near future. For all its benefits, telehealth also has the potential to worsen disparities in health care (22, 23) , particularly among patients who are unhoused or with poor access to technology. Moreover, we have already seen that the coronavirus pandemic has further exacerbated racial disparities and is disproportionately affecting Black and Latinx populations (24) . Analogous to approaches applied in the global health arena, strategies such as using community health workers and providing virtual communication devices with affordable internet (25) will be crucial in ensuring equity for the care of all communities. Special attention should also be paid to ensure virtual care delivery VIEWPOINTS is age friendly, and we should engage family members to help patients navigate the use of electronic devices when needed. Rearranging visits to promote outpatient pulmonary facilities requires a thorough consideration of major structural resources, including staff, personal protective equipment, and testing. Because these will vary regionally and temporally, we suggest a rolling line of communication among the leadership of clinical divisions, clinics, PFT labs, and bronchoscopy suites to examine their availability in the context of local trends in coronavirus infections. To avoid inertia, active vigilance and ongoing modulations based on weekly updated case counts and demands for outpatient facilities can guide frequent reassessment and expansion or restrictions of these services as time progresses. Although our intensivists are restructuring ICUs, generating new evidence, and planning for the impending rise in patients suffering from postintensive care syndrome, the outpatient pulmonologists have incredibly important challenges to address in the next phase of this pandemic. We can only fight the unforeseen consequences of care deferred by preparing and planning for this future state. n Author disclosures are available with the text of this article at www.atsjournals.org. The untold toll: the pandemic's effects on patients without covid-19 A second, hidden pandemic will follow covid-19: we need to plan for it Pandemic shock threatens to undermine outpatient car Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans Virtually perfect? Telemedicine for covid-19 Teladoc's remote doctor visits surge in coronavirus crisis Covid-19: cancer mortality could rise at least 20% because of pandemic, study finds Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency Public health impact of the 2014-2015 Ebola outbreak in West Africa: seizing opportunities for the future Collateral effect of covid-19 on stroke evaluation in the United States Where have all the heart attacks gone? New York: The New York Times Doctors worry the coronavirus is keeping patients away from US hospitals as ER visits drop: 'Heart attacks don't stop Reductions in heart failure hospitalizations during the COVID-19 pandemic Declining cirrhosis hospitalizations in the wake of the COVID-19 pandemic: a national cohort study Reduced rate of hospital admissions for ACS during covid-19 outbreak in northern Italy Lombardia CARe Researchers. Out-of-hospital cardiac arrest during the covid-19 outbreak in Italy Risk stratification for workers during the covid-19 pandemic Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis Home monitoring in patients with idiopathic pulmonary fibrosis: a randomized controlled trial Safety, feasibility, and effectiveness of virtual pulmonary rehabilitation in the real world Caring for patients with cancer in the COVID-19 era Ensuring the growth of telehealth during COVID-19 does not exacerbate disparities in care Addressing equity in telemedicine for chronic disease management during the covid-19 pandemic COVID-19 and racial/ ethnic disparities Mobile data: why India has the world's cheapest Acknowledgment: The authors thank Dr. Carlos P. Cardenas and Dr. Rosechelle M. Ruggiero for engaging conversations that inspired this article. They also thank Dr. Rupal Shah and Dr. Lorri Leard for their clinic leadership.